United States was Valneva SE’s largest region in fiscal 2024, bringing in $48.59M of $169.58M (29%).
| Geography | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|---|---|
| United Kingdom | — | $181.13M | $20.27M | $19.49M | |
| Us Government Department Of Defense | — | — | — | — | |
| United States | $54.79M | -$23.80M | $32.96M | $48.59M | |
| Germany | $966.00K | $68.53M | $13.50M | $18.37M | |
| Canada | $4.23M | $18.90M | $28.19M | $32.32M | |
| Austria | — | $21.79M | $14.58M | $15.90M | |
| France | $1.37M | $46.61M | $5.87M | $7.22M | |
| Rest Of World | — | $17.36M | $16.31M | $4.69M | |
| Other Europe | — | $18.74M | $9.34M | $9.06M | |
| Nordics | $2.44M | $12.04M | $12.70M | $13.94M | |
| Total | $63.79M | $361.30M | $153.71M | $169.58M |
Valneva SE brought in $169.58M from its nine regions in fiscal 2024, the year ended December 31, 2024. That was up 10.3% from $153.71M in fiscal 2023. United States was the largest at $48.59M (28.7%), ahead of Canada at $32.32M (19.1%) and United Kingdom at $19.49M (11.5%). The other six regions brought in $69.18M combined.
Compared with fiscal 2023, United States grew fastest, up 47.4% to $48.59M, while Rest Of World fell the most, down 71.2% to $4.69M.
Valneva SE began breaking out United Kingdom in fiscal 2022, Austria in fiscal 2022, Rest Of World in fiscal 2022 and Other Europe in fiscal 2022.
Ixiaro® was Valneva SE’s largest revenue line in fiscal 2024, bringing in $94.07M of $163.26M (58%).
| Products and services [axis] | FY 2020 | FY 2020 | FY 2021 | FY 2022 | FY 2024 |
|---|---|---|---|---|---|
| Covid Vla2001 | — | $169.20M | — | ||
| Ixiaro® | — | $41.40M | $94.07M | ||
| Ixiaro | $45.12M | — | — | ||
| Lyme Vla15 | — | $45.90M | — | ||
| Third Party Products | $15.43M | $26.50M | $33.19M | ||
| Dukoral® | — | $17.34M | $32.30M | ||
| Dukoral | $2.44M | — | — | ||
| Chikungunya Vla1553 | — | $5.57M | — | ||
| Ixchiq® | — | — | $3.70M | ||
| Services Related To Clinical Trial Material | — | $3.21M | — | ||
| Others | — | $2.78M | — | ||
| Total | $62.98M | $311.88M | $163.26M |
Valneva SE brought in $163.26M from its four revenue lines in fiscal 2024, the year ended December 31, 2024. Valneva SE regrouped these revenue lines after fiscal 2022, so the total does not compare directly with that year's $311.88M. Ixiaro® was the largest at $94.07M (57.6%), ahead of Third Party Products at $33.19M (20.3%) and Dukoral® at $32.30M (19.8%). The remaining revenue line, Ixchiq®, brought in $3.70M.
Compared with fiscal 2022, the previous year with figures, Ixiaro® grew fastest, up 127.2% to $94.07M. Every revenue line above 2% of revenue grew.
Valneva SE began breaking out Ixchiq® in fiscal 2024, when it brought in $3.70M. Valneva SE stopped reporting Covid Vla2001 ($169.20M in fiscal 2022), Lyme Vla15 ($45.90M in fiscal 2022), Ixiaro ($45.12M in fiscal 2021) and four others as separate revenue lines.
Direct Product Sales was Valneva SE’s largest revenue line in fiscal 2024, bringing in $137.89M of $163.25M (84%).
| Sales channels [axis] | FY 2020 | FY 2021 | FY 2024 |
|---|---|---|---|
| Direct Product Sales | $60.31M | $137.89M | |
| Indirect Product Sales | — | $25.37M | |
| Indirect Product Sales (Sales Through Distributors) | $2.68M | — | |
| Total | $62.98M | $163.25M |
Valneva SE brought in $163.25M from its two revenue lines in fiscal 2024, the year ended December 31, 2024. Valneva SE regrouped these revenue lines after fiscal 2021, so the total does not compare directly with that year's $62.98M. Direct Product Sales was the largest at $137.89M (84.5%), ahead of Indirect Product Sales at $25.37M (15.5%).
Valneva SE began breaking out Indirect Product Sales in fiscal 2024, when it brought in $25.37M. Valneva SE stopped reporting Indirect Product Sales (Sales Through Distributors) as a separate revenue line after fiscal 2021, when it brought in $2.68M.
Valneva SE (VALN) reports its revenue by geography, by products and services [axis] and by sales channels [axis]. In fiscal 2024, United States was its largest region, bringing in $48.59M (28.7% of the total), followed by Canada at $32.32M (19.1%).
United States was Valneva SE's largest region in fiscal 2024, bringing in $48.59M, or 28.7% of the $169.58M total across its nine regions.
Ixiaro® was Valneva SE's largest revenue line in fiscal 2024, bringing in $94.07M, or 57.6% of the $163.26M total across its four revenue lines.
Among Valneva SE's regions that make up at least 2% of revenue, United States grew fastest in fiscal 2024, up 47.4% from $32.96M to $48.59M.
Every figure comes from Valneva SE's annual financial filings, as reported. Each line keeps the name Valneva SE gives it, and years follow its fiscal calendar.
Valneva SE's revenue by geography goes back to fiscal 2020, with figures through fiscal 2024. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.